This study was retrospectively registered. The goal of this single-arm, single-center, prospective clinical trial is to evaluate the effectiveness and safety of autologous apheresis platelet-rich plasma (PRP) injection in the treatment of androgenetic alopecia (AGA). The main questions it aims to answer are: * Is apheresis PRP effective in improving hair growth outcomes in male patients with AGA? * Is treatment response associated with key variables, including patient age, number of treatment sessions, baseline severity, and PRP cellular composition? * Does PRP injection lead to any serious adverse events in the treatment of AGA? Researchers will record the effectiveness and adverse events following autologous apheresis PRP treatment for AGA and perform statistical analyses to evaluate treatment outcomes and their correlates with the variables of interest. Participants will: * Receive 3 to 5 sessions of autologous apheresis PRP injections into the scalp at intervals of 3-5 weeks. * Have standardized photographs of the scalp taken from four angles (frontal, vertex, and bilateral sides) prior to each PRP injection. * Attend a follow-up clinic visit or complete a telephone assessment one month after the final PRP injection.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Response Based on the Basic and Specific (BASP) classification
Timeframe: Baseline (pre-first injection) and End of treatment (pre-final injection, ranging from Week 9 to Week 25)